 follow-up of the RESILIENT study, freedom from
target lesion revascularization and clinical success was
signiﬁcantly higher in the primary stent cohort, but no
data were available on patency.210
The Study for Evaluating Endovascular Treatments of
Lesions in the Superﬁcial Femoral Artery and Proximal
Popliteal By Using the Protege EverfLex Nitinol Stent System II (DURABILITY II